Jaguar Health, Inc. (NASDAQ:JAGX) Short Interest Up 138.4% in October

Jaguar Health, Inc. (NASDAQ:JAGX) saw a large growth in short interest in October. As of October 31st, there was short interest totalling 332,300 shares, a growth of 138.4% from the October 15th total of 139,400 shares. Approximately 4.3% of the shares of the company are short sold. Based on an average daily trading volume, of 312,000 shares, the days-to-cover ratio is currently 1.1 days.

Analyst Ratings Changes

Separately, StockNews.com upgraded shares of Jaguar Health from a “sell” rating to a “hold” rating in a research note on Friday, September 13th.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Jaguar Health stock. Perritt Capital Management Inc acquired a new position in Jaguar Health, Inc. (NASDAQ:JAGX) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 25,000 shares of the biotechnology company’s stock, valued at approximately $90,000. Perritt Capital Management Inc owned approximately 0.51% of Jaguar Health at the end of the most recent reporting period. Hedge funds and other institutional investors own 12.04% of the company’s stock.

Jaguar Health Price Performance

Jaguar Health stock traded down $0.08 during mid-day trading on Friday, reaching $0.96. 220,630 shares of the stock traded hands, compared to its average volume of 742,778. Jaguar Health has a 12-month low of $0.90 and a 12-month high of $30.86. The business’s 50-day moving average is $1.14 and its 200-day moving average is $3.67. The company has a quick ratio of 1.60, a current ratio of 2.10 and a debt-to-equity ratio of 1.32.

Jaguar Health (NASDAQ:JAGX) last issued its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($4.04) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($2.84). The business had revenue of $2.72 million during the quarter. Jaguar Health had a negative return on equity of 341.34% and a negative net margin of 360.13%. Equities research analysts anticipate that Jaguar Health will post -0.78 earnings per share for the current year.

Jaguar Health Company Profile

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.